Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209415 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13698136 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8219352 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14255648 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13698137 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4185668 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4912928 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8218431 | 0.78 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14124610 | 0.77 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4923773 | 0.74 | HTT (0.39) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194726-A1 | CRYSTALLINE COMPOUNDS | AMRI SSCI, LLC | 2018-07-12 | — | — | US | disclosed |
| US-9856217-B2 | Crystalline compounds | NEUROVANCE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170334850-A1 | CRYSTALLINE COMPOUNDS | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9708261-B2 | Crystalline compounds | NEUROVANCE, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160368871-A1 | CRYSTALLINE COMPOUNDS | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368871-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A4 3216/4885SLC6A3 3390/4885SLC6A2 3822/4885 |
| US-20180194726-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A4 3216/4885SLC6A3 3390/4885SLC6A2 3822/4885 |
| US-20170334850-A1 | CRYSTALLINE COMPOUNDS | NT5C, NT5C3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A4 3216/4885SLC6A3 3390/4885SLC6A2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.